Alzheimer’s disease (AD), the leading cause of dementia, is a devastating progressive neurodegenerative disease. AD symptoms vary among individuals and are characterised by a progressive loss of memory accompanied by emotional changes, hallucinations, delusions and impaired social behaviour, leading to an increased need for around-the-clock care in the final stages of the disease.
Worldwide, nearly 44 million people have AD or a related dementia and it is estimated to affect 131.5 million individuals by 2050.1 AD statistics are alarming: the rate of sufferers doubles every 5 years after the age of 65, reaching 30–50% in those 85 and older. Dementia will cost the global societal economy $818 billion, one reason why the G8 and US Congress have made finding treatment for AD by 2025 a top priority.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.